New Phase I Study Announcement Of Interleukin-7 As Immunotherapy In Treatment Of Bone Marrow Or Peripheral Blood Stem Cell Transplant Patients
May 15th 2008Drug InformationTransplants
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I clinical trial of its lead investigational drug candidate, Interleukin-7 (IL-7), also known as CYT107. This new trial will study the use of IL-7 / CYT107 in the treatment of post-transplant patients with T-cell depleted bone marrow or peripheral blood stem cell transplants.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
